EGFR and non-small cell lung carcinoma: In the NSCLC cohort, the ORR was 52.5% (95% confidence interval (CI): 37.5–67.1%) in patients with EGFR mutations and 30.6% (95% CI: 20.6–43.0%) in patients with wild-type EGFR (Figure 1) (Table 1).